Novo Nordisk announced it will reduce the U.S. list price of Wegovy, Ozempic, and Rybelsus to $675 per month beginning Jan. 1, 2027—representing an approximate 50% reduction for Wegovy and 35% for Ozempic across all doses. The company stated the change is designed to improve affordability for patients whose out-of-pocket costs are tied to list prices, such as those with high-deductible plans or coinsurance, and will not impact existing self-pay options like NovoCare. The adjustment coincides with broader federal drug pricing reforms, as the Centers for Medicare & Medicaid Services will implement new maximum fair prices in 2027 for select high-expenditure Medicare Part D drugs—including these three medications—lowering the negotiated monthly price to $274 from the 2024 list price of $959.
Resource: Novo Nordisk to lower list price of Wegovy, Ozempic in 2027